Increase in prevalence of various cancer types, rise in demand for cost-efficient biosimilar monoclonal antibodies, and upsurge in likelihood of epidemic or pandemic outbreaks drive the growth of the global Monoclonal Antibodies (MAbS) Market. On the other hand, poor
source https://www.openpr.com/news/2381397/monoclonal-antibodies-mabs-market-expected-to-reach-390-58